HOUSTON, TX — A Phase 2 clinical trial conducted by the University of Texas MD Anderson Cancer Center has demonstrated that the senolytic combination of dasatinib and quercetin (D+Q) significantly slows the decline in forced vital capacity (FVC) in patients with Idiopathic Pulmonary Fibrosis (IPF) [Source: MD Anderson News Room]. The results, presented at the European Respiratory Society (ERS) International Congress, provide the first clinical evidence that targeting cellular senescence can modify the disease trajectory of this fatal, progressive lung disorder.

The Pathophysiology of Cellular Senescence in IPF

IPF is characterized by the progressive scarring (fibrosis) of the lung interstitium, leading to a relentless decline in respiratory function and a median survival of 3 to 5 years post-diagnosis. The underlying pathology is driven by repeated micro-injuries to the alveolar epithelial cells (AECs). In aging lungs, these injured AECs fail to undergo apoptosis or regenerate; instead, they enter a state of cellular senescence.

Senescent cells are metabolically active but irreversibly arrested in the cell cycle. Crucially, they secrete a complex mixture of pro-inflammatory cytokines, chemokines, and proteases known as the senescence-associated secretory phenotype (SASP). The SASP creates a toxic microenvironment that activates fibroblasts, driving their differentiation into myofibroblasts, which deposit excessive extracellular matrix (collagen) and destroy the lung architecture.

Mechanism of the D+Q Senolytic Regimen

Senolytics are a novel class of therapeutics designed to induce selective apoptosis in senescent cells while sparing healthy, proliferating cells. Dasatinib, a tyrosine kinase inhibitor, and quercetin, a flavonoid, act synergistically to inhibit the pro-survival signaling pathways (such as PI3K/AKT and BCL-2 family proteins) that senescent cells rely on to resist apoptosis. By clearing the senescent cell burden, the D+Q regimen effectively removes the source of the SASP, thereby reducing the chronic inflammatory and fibrotic drive in the lung tissue.

The Phase 2 trial enrolled 120 patients with mild-to-moderate IPF. Patients received intermittent oral doses of D+Q for three consecutive days every two weeks for a total of 12 weeks. The primary endpoint was the change in FVC from baseline to week 24. The D+Q group exhibited a mean FVC decline of only 45 mL, compared to a decline of 180 mL in the placebo group, representing a 75% reduction in the rate of functional decline.

Safety Profile and Biomarker Validation

The safety profile of the intermittent D+Q regimen was favorable. The most common adverse events were mild, transient fatigue and gastrointestinal disturbances, consistent with the known side effects of the individual drugs. There were no significant hematologic toxicities or hepatic injuries. To confirm the mechanism of action, researchers measured circulating levels of p16^INK4a^ mRNA and the SASP cytokine IL-6. Both biomarkers showed a significant, sustained reduction in the D+Q group, confirming the successful clearance of the senescent cell burden.

Implications for Age-Related Fibrotic Diseases

The success of D+Q in IPF has profound implications for the broader field of geroscience. IPF is fundamentally a disease of lung aging, and the senolytic approach targets the fundamental biological mechanism of aging itself—the accumulation of senescent cells. If these results are confirmed in a pivotal Phase 3 trial, D+Q, or next-generation senolytics with improved specificity, could become the standard of care for IPF, replacing or augmenting current antifibrotics like pirfenidone and nintedanib, which only modestly slow disease progression and possess significant toxicity profiles. Furthermore, this paradigm extends to other age-related fibrotic conditions, including liver cirrhosis, cardiac fibrosis, and chronic kidney disease.

Related Topics:

#Senolytics#IPF#Pulmonary Fibrosis#Aging Research#Clinical Trial#Dasatinib#Quercetin#Geroscience
ayesha
ayeshaStaff Writer

Related Articles

Comments (0)

No comments yet. Be the first to share your thoughts!